Hamps Bio Acquires HSDL Innovative to Bolster Food Processing

Purchase consideration: ₹2.04 crore (₹204.00 lakh) cash for 100% stake. HSDL Innovative Private Limited is now a Wholly Owned Subsidiary.

The Deal Details

Hamps Bio Ltd. has completed its acquisition of 100% of HSDL Innovative Private Limited. The total purchase price was ₹2.04 crore, paid entirely in cash. As of March 25, 2026, HSDL Innovative Private Limited is now a wholly owned subsidiary of Hamps Bio Ltd. This deal, initially announced on February 14, 2026, marks a strategic consolidation.

Expanding Food Capabilities

This acquisition will bolster Hamps Bio's existing freeze-dried food ingredient business, which operates under the 'FzyEzy' brand. The move aims to integrate HSDL's capabilities and product portfolio, strengthening Hamps Bio's position in the food processing sector. This consolidation fits a broader trend of capability-focused M&A within India's pharmaceutical and healthcare sectors.

Company Background

Hamps Bio Ltd., founded in 2007, operates in pharmaceutical formulations and the freeze-dried ingredient FMCG market. It converted to a Public Limited Company in 2023. The company already participates in the freeze-dried market with its 'FzyEzy' brand, serving both B2B and B2C customers. HSDL Innovative Private Limited, founded in 2017, specializes in freeze-dried fruits, vegetables, herbs, and ready-to-eat food products.

Integration and Synergies

HSDL Innovative Private Limited will be fully integrated into Hamps Bio's operations, aiming for operational synergies. The combined entity will offer a wider range of products in the freeze-dried food segment.

Financial Challenges and Risks

Hamps Bio recently reported financial challenges, including a net loss of ₹19.50 Lakhs for the six months ended September 30, 2025. This marks a significant shift from its previous profitability. The company's stock price has also declined significantly, falling 42.84% over the past year, reflecting investor concerns. Revenue from operations also fell 40.41% year-on-year during the same six-month period. Key risks include the integration process and the company's ability to realize synergies from the acquisition.

Industry Consolidation Trends

Major pharmaceutical players, such as Torrent Pharmaceuticals and Sun Pharmaceutical Industries, are actively pursuing strategic acquisitions, mirroring an industry-wide trend toward consolidation and capability building. Torrent Pharma's significant acquisition of a stake in JB Chemicals & Pharmaceuticals illustrates the scale of strategic M&A in the sector.

Key Financial Metrics

• HSDL Innovative Private Limited reported a turnover of ₹1.87 crore for FY25.
• Hamps Bio Ltd. reported a net loss of ₹19.50 Lakhs for the six months ended September 30, 2025 (standalone).

Investor Focus

• Successful integration of HSDL Innovative Private Limited's operations and management into Hamps Bio's structure.
• Performance of the consolidated food processing division and its contribution to the company's financial recovery.
• How the company addresses its recent financial performance, including its reported losses and revenue decline.
• Future strategic initiatives or expansions within its food ingredients or pharmaceutical segments.